4Lyman GH, Barron RL, Natoli JL, et al. Systematic review of efficacy of dose-dense versus non-dose-dense chemo- therapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer[J]. Crit Rev Oneol Hematol, 2012,81(3):296-308.
5Hardy D, Cormier JN, Xing Y, et al.Chemotherapy- associated toxicity in a large cohort of elderly patients with non-small cell lung cancer[J].J Thorac Oncol, 2010, 5(1):90.
6Hollen P J, Gralla RJ, Kris MG, et al. Quality of Life Assessment in Individuals with Lung Cancer:Testing the Lung Cancer Symptom Scale(LCSS)[J].Eur J Cancer, 1993, 29A(SuoD1 1):$51.
7Heukamp LC, Biittner R. Molecular diagnostics in lung carcinoma for therapy stratification[J].Pathologe, 2010, 31(1):22.
8Dudek AZ, Kmak KL, Koopmeinem J, et al. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non - small celllung cancer [ J]. Lung Cancer, 2006, 51 (1): 89-96.
9Mok TS, Wu YL, Yu CJ, et al. Randomized, placebo - controlled, phase H study of sequential erlotinib and chemotherapy as first - line treatment for advaneed non - small - cell lung cancer [ J ]. J Clin Oneol, 2009, 27 (30) : 5080 -5087.
10Sun,Y,Wu,Y.-L,Zhou,C,et al.Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer:A randomized,open-label study[J].Lung cancer,2013,79(2):143.
